
Keywords: Personalized medicine; primary immunodeficiency disorders; immune dysregulation; autoimmunity; therapy; mutation; APDS; Activated phosphoinositide 3-kinase syndrome; CMC; Chronic mucocutaneous candidiasis; CTLA4; Cytotoxic lymphocyte antigen 4; GOF; Gain